US5055489A - Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events - Google Patents
Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events Download PDFInfo
- Publication number
- US5055489A US5055489A US07/518,892 US51889290A US5055489A US 5055489 A US5055489 A US 5055489A US 51889290 A US51889290 A US 51889290A US 5055489 A US5055489 A US 5055489A
- Authority
- US
- United States
- Prior art keywords
- hypoxic
- control
- felbamate
- slices
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 32
- 230000001146 hypoxic effect Effects 0.000 title claims abstract description 27
- 230000006378 damage Effects 0.000 title claims abstract description 17
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims abstract description 8
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 7
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 229960003472 felbamate Drugs 0.000 description 24
- 238000011084 recovery Methods 0.000 description 16
- 230000000763 evoking effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- -1 etc. Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
Definitions
- the present invention relates to pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate as an active component and to methods for the prevention and control of hypoxic damage resulting from stroke or other ischemic event through the use of such compositions.
- the present invention relates to methods for protecting against hypoxic damage resulting from stroke and other cerebral ischemic events through the administration of therapeutic compositions which contain as an active ingredient 2-phenyl-1,3-propanediol dicarbamate, commonly known as Felbamate.
- Felbamate is a well known pharmaceutical compound having been described together with methods for its manufacture in U.S. Pat. Nos. 2,884,444 and 4,868,327.
- One of the objects of the present invention is to provide compositions for the prevention and control of hypoxic damage.
- Another object of the present invention is to provide relatively non-toxic compositions effective to control or prevent hypoxic damage resulting from stroke or other cerebral ischemic event which include felbamate as an active component.
- a further object of the present invention is to provide compositions for the prevention and control of hypoxic damage which compositions are relatively non-toxic, have a high degree of effectiveness and continue to produce a therapeutic response over relatively long periods of time.
- felbamate chemically described as 2-phenyl-1,3-propanediol dicarbamate is a compound which has demonstrated superior properties with respect to controlling and/or preventing hypoxic damage resulting from stroke or other ischemic cerebral event.
- Sprague-Dawley rats are briefly anesthetized with Halothane and then decapitated. The brain is removed and the hippocampus dissected. Transverse hippocampal brain slices of 475 microns are sectioned with a McIlwain tissue chopper. Slices are then incubated in a temperature controlled chamber of 34 degrees centigrade while being perfused with an artificial cerebral spinal fluid (NaCl 126 mM; KCl, 4; KH 2 PO 4 , 1.4; MgSO 4 , 1.3; CaCl 2 , 2.4; NaHCO 3 , 26 and glucose, 4) saturated with 95% O 2 and 5% CO 2 .
- an artificial cerebral spinal fluid NaCl 126 mM
- KCl, 4 KH 2 PO 4
- MgSO 4 1.3
- the slices are tested for electrophysiological function. Electrical stimulation is given in the region of the CA3 collaterals with a bipolar twisted wire electrode. Evoked responses are recorded extracellularly in the pyramidal cell layer of the CA1 region. Stimulation is given for a duration of 40 microseconds in square wave pulses. The peak-to-peak amplitude of the resultant evoked potential response is then monitored.
- Hippocampal slices from one animal are placed in two chambers.
- One chamber is used as a control and receives standard artificial cerebral spinal fluid (ACSF) while the second receives felbamate.
- ACSF artificial cerebral spinal fluid
- one slice is stimulated every 30 seconds to monitor evoked potential response.
- Other slices in the chamber are not continuously stimulated. In these latter slices, designated as non-stimulated, the evoked potential response is assessed only at the beginning and end of the experiment. Only slices with initial evoked potentials of 3 mV or greater amplitude are included for testing.
- the experimental chamber is perfused with oxygenated artificial cerebral spinal fluid (ACSF) containing felbamate for 30 minutes before the initiation of hypoxic conditions.
- the control chamber continues to receive oxygenated ACSF without felbamate during this period. Hypoxic conditions are then initiated simultaneously in both chambers by changing to perfusing media saturated with 95% N 2 and 5% CO 2 .
- the experimental chamber receives nitrogenated ACSF with felbamate while the control chamber receives nitrogenated ACSF without felbamate.
- hypoxic injury potential HIP
- hippocampal slices can vary in their temporal response to hypoxia, the HIP is a reliable marker of permanent hypoxic injury. For this reason, the disappearance of the HIP is chosen to determine length of hypoxic exposure. Hypoxia is continued in both chambers for 5 minutes beyond the disappearance of the HIP in the stimulated control slice.
- Felbamate perfusion produced occasional transient collapse and disappearance of the evoked potential, but no evidence of toxicity as evidenced by permanent potential loss was seen.
- This protective action is assessed by several measures.
- evoked potential recovery is assessed in both stimulated and non-stimulated slices.
- hypoxic protection is calculated for both stimulated and non-stimulated slices. This measure is calculated as the damage seen in control slices minus the damage seen in experimental (felbamate) slices divided by the damage seen in control slices. For these purposes damage is defined as 100 percent minus percent recovery.
- the determination of hypoxic protection helps take into account any survival seen in control slices.
- counts of total surviving slices were made. For this purpose a minimal amplitude criteria of 3 mV was used as the indicator of a surviving slice.
- compositions of the present invention may take any of a variety of forms although they are intended primarily for oral use and are suitable for forming into pills, capsules and tablets by well-known practices.
- active ingredient is in the form of a solid
- a typical tablet composition comprises 2-phenyl-1,3-propanediol dicarbamate intermixed in a dry pulverulent state with suitable solid carriers and diluents.
- Solid carriers and diluents suitable for use include sugars such as lactose and sucrose; cellulose derivatives such as carboxymethyl cellulose, ethyl cellulose, methyl cellulose, etc., gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
- the percentage of 2-phenyl-1,3-propanediol dicarbamate in the compositions may be varied over wide limits and the quantity of medicament furnished by each individual tablet or capsule is relatively unimportant since the indicated total daily dose can be reached by administering either one or a plurality of capsules or tablets.
- Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a very favorable preclinical profile characterized by a substantial margin of safety (protective index 16.9-19.1).
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for the prevention and control of hypoxic damage resulting from stroke or other cerebral ischemic event which comprises administering pharmaceutical compositions containing 2-phenyl-1, 3-propanediol dicarbamate as an active ingredient.
Description
The present invention relates to pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate as an active component and to methods for the prevention and control of hypoxic damage resulting from stroke or other ischemic event through the use of such compositions.
More particularly, the present invention relates to methods for protecting against hypoxic damage resulting from stroke and other cerebral ischemic events through the administration of therapeutic compositions which contain as an active ingredient 2-phenyl-1,3-propanediol dicarbamate, commonly known as Felbamate.
Felbamate is a well known pharmaceutical compound having been described together with methods for its manufacture in U.S. Pat. Nos. 2,884,444 and 4,868,327.
One of the objects of the present invention is to provide compositions for the prevention and control of hypoxic damage.
Another object of the present invention is to provide relatively non-toxic compositions effective to control or prevent hypoxic damage resulting from stroke or other cerebral ischemic event which include felbamate as an active component.
A further object of the present invention is to provide compositions for the prevention and control of hypoxic damage which compositions are relatively non-toxic, have a high degree of effectiveness and continue to produce a therapeutic response over relatively long periods of time.
Moreover, it is an object of the present invention to provide methods for the prevention and control of hypoxic damage through the use of felbamate.
Accordingly, it has been found that felbamate chemically described as 2-phenyl-1,3-propanediol dicarbamate is a compound which has demonstrated superior properties with respect to controlling and/or preventing hypoxic damage resulting from stroke or other ischemic cerebral event.
The neuro-protective effects of felbamate against hypoxic damage were investigated in the hippocampal slice model as described in the following example. This in vitro model simulates in vivo hypoxic-ischemic neuronal insults such as occur in stroke and other cerebral ischemic events.
Sprague-Dawley rats are briefly anesthetized with Halothane and then decapitated. The brain is removed and the hippocampus dissected. Transverse hippocampal brain slices of 475 microns are sectioned with a McIlwain tissue chopper. Slices are then incubated in a temperature controlled chamber of 34 degrees centigrade while being perfused with an artificial cerebral spinal fluid (NaCl 126 mM; KCl, 4; KH2 PO4, 1.4; MgSO4, 1.3; CaCl2, 2.4; NaHCO3, 26 and glucose, 4) saturated with 95% O2 and 5% CO2.
After an initial one hour equilibration period, the slices are tested for electrophysiological function. Electrical stimulation is given in the region of the CA3 collaterals with a bipolar twisted wire electrode. Evoked responses are recorded extracellularly in the pyramidal cell layer of the CA1 region. Stimulation is given for a duration of 40 microseconds in square wave pulses. The peak-to-peak amplitude of the resultant evoked potential response is then monitored.
Hippocampal slices from one animal are placed in two chambers. One chamber is used as a control and receives standard artificial cerebral spinal fluid (ACSF) while the second receives felbamate. In each chamber, one slice is stimulated every 30 seconds to monitor evoked potential response. Other slices in the chamber are not continuously stimulated. In these latter slices, designated as non-stimulated, the evoked potential response is assessed only at the beginning and end of the experiment. Only slices with initial evoked potentials of 3 mV or greater amplitude are included for testing.
The experimental chamber is perfused with oxygenated artificial cerebral spinal fluid (ACSF) containing felbamate for 30 minutes before the initiation of hypoxic conditions. The control chamber continues to receive oxygenated ACSF without felbamate during this period. Hypoxic conditions are then initiated simultaneously in both chambers by changing to perfusing media saturated with 95% N2 and 5% CO2. The experimental chamber receives nitrogenated ACSF with felbamate while the control chamber receives nitrogenated ACSF without felbamate.
The duration of hypoxic exposure for both chambers is determined by the disappearance of the hypoxic injury potential (HIP) in the control stimulated slice. This potential appears during hypoxia after the disappearance of the original evoked potential. Although hippocampal slices can vary in their temporal response to hypoxia, the HIP is a reliable marker of permanent hypoxic injury. For this reason, the disappearance of the HIP is chosen to determine length of hypoxic exposure. Hypoxia is continued in both chambers for 5 minutes beyond the disappearance of the HIP in the stimulated control slice.
After hypoxic exposure, slices are monitored through one hour of recovery with oxygenated ACSF. The felbamate chamber receives oxygenated ACSF with felbamate for the first 15 minutes of this recovery and then standard oxygenated ACSF for the remaining 45 minutes of recovery. After a one-hour recovery period, the percentage of evoked potential amplitude recovery is assessed in both stimulated and non-stimulated slices. This percentage is calculated as the evoked potential amplitude after recovery divided by the evoked potential amplitude prior to hypoxic exposure.
The results of the foregoing procedure are as follows:
a. Pre-hypoxic Incubation.
Felbamate perfusion produced occasional transient collapse and disappearance of the evoked potential, but no evidence of toxicity as evidenced by permanent potential loss was seen.
b. Hypoxic Neuro-protection.
Significant neuro-protection against hypoxia is seen at felbamate concentrations of 380 uM, 840 uM, 1,300 uM and 1,700 uM.
This protective action is assessed by several measures. First, evoked potential recovery is assessed in both stimulated and non-stimulated slices. Additionally, hypoxic protection is calculated for both stimulated and non-stimulated slices. This measure is calculated as the damage seen in control slices minus the damage seen in experimental (felbamate) slices divided by the damage seen in control slices. For these purposes damage is defined as 100 percent minus percent recovery. The determination of hypoxic protection helps take into account any survival seen in control slices. Lastly, counts of total surviving slices were made. For this purpose a minimal amplitude criteria of 3 mV was used as the indicator of a surviving slice.
In stimulated control slices, hypoxic exposure resulted in near complete loss (1.0% mean recovery) of the population spike, while slices treated with 4, 190, 380, 840, 1,300 and 1,700 uM felbamate showed respectively 2%, 6%, 13%, 46%, 95% and 96% recovery. This recovery is significant at p 0.05 for 840 uM and significant at p 0.001 for concentrations of 1,300 and 1,700 uM. Since recovery in the stimulated control slices is minimal, calculated protection was essentially identical to recovery. Counts of surviving stimulated slices indicated substantial felbamate protection at doses of 1,300 and 1,700 uM. Interestingly, 1,700 uM felbamate delayed the appearance of the HIP by 14.5 minutes (p 0.05) but did not affect the disappearance of the evoked potential.
In non-stimulated control slices, recovery from hypoxic exposure shows greater recovery than stimulated control slices and a mean non-stimulated control recovery of 30% is seen. Calculated protection with felbamate concentrations of 4, 190, 380, 840, 1,300 and 1,700 uM, show respective values of 4%, 63%, 48%, 100% and 100%. Additionally, counts of surviving non-stimulated slices showed substantial protection.
The foregoing example indicates a significant hypoxic neuro-protective effect with felbamate within a wide concentration range (380 to 1,700 uM) in the hippocampal slice hypoxic model. Felbamate's hypoxic EC50 in vitro appears to fall between its anticonvulsant ED50 for MES (46 mg/kg) and metrazol (238 mg/kg) in rats. At high concentration of felbamate, no evidence of toxicity for electrophysiological function is seen.
The compositions of the present invention may take any of a variety of forms although they are intended primarily for oral use and are suitable for forming into pills, capsules and tablets by well-known practices. When the active ingredient is in the form of a solid, a typical tablet composition comprises 2-phenyl-1,3-propanediol dicarbamate intermixed in a dry pulverulent state with suitable solid carriers and diluents.
Solid carriers and diluents suitable for use include sugars such as lactose and sucrose; cellulose derivatives such as carboxymethyl cellulose, ethyl cellulose, methyl cellulose, etc., gelatin including hard and soft gelatin capsules, talc, cornstarch, stearic acid and magnesium stearate.
The percentage of 2-phenyl-1,3-propanediol dicarbamate in the compositions may be varied over wide limits and the quantity of medicament furnished by each individual tablet or capsule is relatively unimportant since the indicated total daily dose can be reached by administering either one or a plurality of capsules or tablets.
Felbamate (2-phenyl-1,3-propanediol dicarbamate) has a very favorable preclinical profile characterized by a substantial margin of safety (protective index 16.9-19.1).
It should be understood that the above examples are illustrative of the best mode only of the invention herein disclosed. Given the present disclosure, it is anticipated that numerous variations will occur to those skilled in the art. A latitude of modification, substitution and change is intended and in some instances, some features of the invention will be employed without a corresponding use of other features. Accordingly, it is intended that the spirit and scope of the invention disclosed herein should be limited only by the following claims.
Claims (1)
1. A method for the prevention and treatment of hypoxic damage following a stroke or other cerebral ischemic events in human or other warm-blooded animal patient which comprises administering to said patient in need of such treatment 2-phenyl-1,3-propanediol dicarbamate.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/518,892 US5055489A (en) | 1990-05-04 | 1990-05-04 | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events |
| EP91304644A EP0514598A1 (en) | 1990-05-04 | 1991-05-22 | Use of felbamate in a medicament for the treatment of hypoxic damage |
| US07/966,965 US5256690A (en) | 1990-05-04 | 1992-10-26 | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/518,892 US5055489A (en) | 1990-05-04 | 1990-05-04 | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/966,965 Continuation-In-Part US5256690A (en) | 1990-05-04 | 1992-10-26 | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5055489A true US5055489A (en) | 1991-10-08 |
Family
ID=24065928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/518,892 Expired - Fee Related US5055489A (en) | 1990-05-04 | 1990-05-04 | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US5055489A (en) |
| EP (1) | EP0514598A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0514598A1 (en) * | 1990-05-04 | 1992-11-25 | Carter-Wallace, Inc. | Use of felbamate in a medicament for the treatment of hypoxic damage |
| US5256690A (en) * | 1990-05-04 | 1993-10-26 | Carter-Wallace, Inc. | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders |
| US5290808A (en) * | 1992-11-06 | 1994-03-01 | Carter-Wallace, Inc. | Method to control the intake of food |
| US5462966A (en) * | 1993-10-15 | 1995-10-31 | Carter-Wallace Inc. | Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US6515019B2 (en) * | 1996-04-10 | 2003-02-04 | Walter E. Kozachuk | Methods of providing symptomatic and prophylactic treatment for medical and neurological conditions |
| US6538024B1 (en) | 1999-02-09 | 2003-03-25 | University Of Virginia Patent Foundation | Felbamate derived compounds |
| US20030166648A1 (en) * | 2002-11-01 | 2003-09-04 | Macdonald Timothy L | Felbamate derived compounds |
| US20040023986A1 (en) * | 2000-10-25 | 2004-02-05 | Macdonald Timothy L. | Substituted felbamate derived compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978680A (en) * | 1989-09-26 | 1990-12-18 | Carter-Wallace, Inc. | Method for the prevention and control of epileptic seizure |
| US5055489A (en) * | 1990-05-04 | 1991-10-08 | Carter-Wallace, Inc. | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events |
-
1990
- 1990-05-04 US US07/518,892 patent/US5055489A/en not_active Expired - Fee Related
-
1991
- 1991-05-22 EP EP91304644A patent/EP0514598A1/en not_active Withdrawn
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0514598A1 (en) * | 1990-05-04 | 1992-11-25 | Carter-Wallace, Inc. | Use of felbamate in a medicament for the treatment of hypoxic damage |
| US5256690A (en) * | 1990-05-04 | 1993-10-26 | Carter-Wallace, Inc. | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders |
| US5290808A (en) * | 1992-11-06 | 1994-03-01 | Carter-Wallace, Inc. | Method to control the intake of food |
| US5462966A (en) * | 1993-10-15 | 1995-10-31 | Carter-Wallace Inc. | Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US6515019B2 (en) * | 1996-04-10 | 2003-02-04 | Walter E. Kozachuk | Methods of providing symptomatic and prophylactic treatment for medical and neurological conditions |
| US6538024B1 (en) | 1999-02-09 | 2003-03-25 | University Of Virginia Patent Foundation | Felbamate derived compounds |
| US6599935B2 (en) | 1999-02-09 | 2003-07-29 | University Of Virginia Patent Foundation | Felbamate derived compounds |
| US6759402B2 (en) | 1999-02-09 | 2004-07-06 | University Of Virginia Patent Foundation | Cyclic felbamate derived compounds |
| US20040023986A1 (en) * | 2000-10-25 | 2004-02-05 | Macdonald Timothy L. | Substituted felbamate derived compounds |
| US20030166648A1 (en) * | 2002-11-01 | 2003-09-04 | Macdonald Timothy L | Felbamate derived compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0514598A1 (en) | 1992-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Olney et al. | Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine | |
| Rafiq et al. | Generation and propagation of epileptiform discharges in a combined entorhinal cortex/hippocampal slice | |
| Weinberger et al. | Temporary arrest of the circulation to the central nervous system: II. Pathologic effects | |
| Seneviratne et al. | The effects of hypoxia on the excitability of the isolated peripheral nerves of alloxan-diabetic rats | |
| Jancsó-Gábor et al. | Irreversible impairment of thermoregulation induced by capsaicin and similar pungent substances in rats and guinea-pigs | |
| US4978680A (en) | Method for the prevention and control of epileptic seizure | |
| EP3842047B1 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
| DE60131004T2 (en) | PHARMACEUTICAL PREPARATIONS AGAINST HEADACHE, MIGRAINE, NAUSEA AND HERBAGE | |
| ES2590259T3 (en) | Compounds and procedures for the treatment of seizures and paroxysmal disorders | |
| US5055489A (en) | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events | |
| EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
| DE69413090T2 (en) | Use of 5-amino-phthaloyl hydrazide as an anti-hypoxic and defensive agent | |
| Crossland et al. | The effect on the electrical activity of the cerebellum of a substance present in cerebellar extracts | |
| KR100554319B1 (en) | Use of gamma-aminobutyric acid homologs such as gabapentin in the manufacture of a medicament for the treatment of inflammatory diseases | |
| US4576951A (en) | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief | |
| EP0953352A1 (en) | A therapeutic agent for ischemic diseases | |
| IE911762A1 (en) | Medicament for hypoxic damage | |
| Reele et al. | The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers | |
| US5256690A (en) | Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders | |
| PT98027B (en) | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING 2-PHENYL-1,3-PROPANODIOL DICARBAMATE | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| BAN et al. | The central action of gamma-butyrolactone and gamma-hydroxybutyrate | |
| Habermann | A review of controlled studies with nomifensine, performed outside the UK. | |
| US2775539A (en) | Process of and compositions for combating epileptic seizures with atrolactamide | |
| Nokubo et al. | Age-dependent decrease in the lethal threshold of pentylenetetrazole in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CARTER-WALLACE, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SOFIA, ROBERT D.;REEL/FRAME:005313/0250 Effective date: 19900504 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: LEHMAN COMMERCIAL PAPER INC., NEW JERSEY Free format text: SECURITY AGREEMENT;ASSIGNORS:MEDPOINT INC.;MCC ACQUISITION SUB CORPORATION;MCC MERGER SUB CORPORATION;REEL/FRAME:012530/0854 Effective date: 20010928 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20031008 |
|
| AS | Assignment |
Owner name: MEDPOINTE HEALTHCARE INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:CARTER-WALLACE, INC.;REEL/FRAME:016245/0386 Effective date: 20011001 |
|
| AS | Assignment |
Owner name: MEDPOINTE HEALTHCARE INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:LEHMAN COMMERICAL PAPER INC.;REEL/FRAME:017675/0384 Effective date: 20060524 |